NATIONAL CANCER INSTITUTE (NCI) FORMULARY MATERIAL TRANSFER AGREEMENTNational Cancer Institute • August 23rd, 2021 • District of Columbia
Transfer. Following receipt of all required documentation, NCI agrees to transfer to Institution the following Formulary Agent(s) for use by Approved Investigator in Study described in Attachment A:
NATIONAL CANCER INSTITUTE NANOTECHNOLOGY CHARACTERIZATION LABORATORY MATERIAL TRANSFER AGREEMENTNational Cancer Institute • July 15th, 2020
This Material Transfer Agreement (MTA) permits the exchange of materials and associated information between the parties defined below. Individually or collectively, the parties to this agreement shall also be referred to as “Party” or “Parties” respectively.
NATIONAL CANCER INSTITUTE PEDIATRIC PRECLINICAL IN VIVO TESTING PROGRAM MATERIAL TRANSFER AGREEMENTNational Cancer Institute • September 9th, 2021 • District of Columbia
The NCI-supported Pediatric Preclinical in Vivo Testing Program (PIVOT or NCI Pediatric PIVOT) is a comprehensive program to systematically evaluate new agents against childhood solid tumor and leukemia models. The PIVOT is funded through a National Cancer Institute (NCI) cooperative agreement with each of the participating institutions and the Coordinating Center. Testing occurs at one or more of the following institutions (“Institutions”) with PIVOT investigators (“Institution’s PIVOT Investigator” or “Investigator”): Ann & Robert H. Lurie Children’s Hospital of Chicago (Xiaonan Li), Children’s Cancer Institute Australia (Richard Lock), The Children’s Hospital of Philadelphia (Yael Mosse), University of Texas, MD Anderson Cancer Center (Rickard Gorlick), Sloan Kettering Institute for Cancer Research (Filemon Dela Cruz), St. Jude Children’s Research Hospital (Michael Dyer), and The University of Texas Health Science Center, San Antonio (Peter Houghton). General PIVOT operation and dat
NATIONAL CANCER INSTITUTE OFFICE OF ACQUISTIONSNational Cancer Institute • February 6th, 2020
Document Type: Pre-solicitation Notice Solicitation Number: N02AT020420-27 Posted Date: 02/05/2020 Response Date: 02/21/2020 NAICS Code: 541990 All Other Professional, Scientific, and Technical Services Set Aside: No Set-Aside/Unrestricted
THE NATIONAL CANCER INSTITUTE’S CHEMICAL BIOLOGY CONSORTIUM PARTICIPANTS AGREEMENTNational Cancer Institute • February 9th, 2022 • District of Columbia
This Agreement is between the National Cancer Institute (“NCI”) and the Participant Institution (“Participant”) in the Chemical Biology Consortium (“CBC”). Collectively or individually, the NCI and Participant shall also be referred to as “Party” or “Parties.” The Parties rights and responsibilities in the use and protection of Confidential Information disclosed for the Purpose are outlined in this Agreement.
NATIONAL CANCER INSTITUTE (NCI) FORMULARY MATERIAL TRANSFER AGREEMENT FOR CLINICAL OR NON-CLINICAL RESEARCHNational Cancer Institute • April 28th, 2023
Definitions: All capitalized terms defined herein shall have the meaning consistent with those set forth in the Cooperative Research and Development Agreement (CRADA) between NCI and the NCI Collaborator.
